Monoclonal antibody · Antagonist of C5a receptor (C5AR1) · developed by Innate Pharma
Avdoralimab is a human monoclonal antibody that binds and blocks the C5a receptor (C5aR) on subsets of myeloid-derived suppressor cells and neutrophils, preventing C5a from activating these cells. It is being studied in advanced solid tumors and COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04371367 | Phase 2 | COVID | Completed | IPHA |
| NCT03665129 | Phase 1 | Advanced Solid Tumors | Terminated | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsCOVID
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.
See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPHA catalysts and pipeline →